On May 7, the 60th European Society for Liver Research Annual Meeting (EASL2025) and the 2025 EASL Congress (EASL Congress 2025) opened in Amsterdam, Netherlands. 8,000 scientists, doctors, public health experts, industry representatives and community representatives from around the world gathered.

According to incomplete statistics, 13 research teams in my country published a report on the EASL2025 conference, covering the latest research results in the pathogenesis of liver tumors, liver cancer immunotherapy, cccDNA clearance molecular mechanism, cirrhosis treatment, liver fibrosis cell signaling, fatty liver intestinal flora effect, early diagnosis of liver cancer, interferon treatment of hepatitis B carriers, the impact of hepatitis B RNA interference treatment on immunity, clinical trials of new hepatitis B drugs, treatment of liver failure, metabolic liver disease and molecular diagnosis of liver cancer, etc., reflecting the rapid progress of liver disease research and clinical diagnosis and treatment in my country, and is in an international leading position in some fields. Among them, breakthrough progress has been made in clinical research on new hepatitis B drugs, and the results of the randomized double-blind clinical trial of the hepatitis B virus entry inhibitor Hepratide in the treatment of chronic hepatitis B phase II were announced.

After hepatitis B virus infection, its genomic DNA enters the hepatocyte nucleus and forms cccDNA through covalent cyclization, as a template for progeny virus replication. The persistent existence of cccDNA is the fundamental reason why hepatitis B cannot be cured. Hepratide is an independent original innovative drug for my country and has completely independent intellectual property rights. Its preclinical and clinical research has been approved by major national science and technology projects in the 12th Five-Year Plan and the 13th Five-Year Plan. A randomized double-blind placebo-controlled clinical trial of hepatitis B combined with PEG interferon in the treatment of chronic hepatitis B, reported by the EASL2025 conference, combines a viral entry blocking strategy and an immune regulation strategy for the treatment of chronic hepatitis B. The study results showed that after receiving 24 weeks of combined treatment, some patients had lower liver cccDNA levels than the detection limit, reaching the American Society of Hepatitis Research AASLD-European Society of Liver Research EASL on hepatitis B cure-sterillising cure. The Phase III clinical trial of Hepratin for chronic hepatitis B is about to be launched, and we look forward to benefiting the majority of hepatitis B patients in my country and around the world.

[Editor in charge: Wu Qilong]